Assertio Therapeutics, Inc. (ASRT)
| Market Cap | 80.85M |
| Revenue (ttm) | 112.20M |
| Net Income (ttm) | -64.83M |
| Shares Out | 173.79M |
| EPS (ttm) | -0.53 |
| PE Ratio | n/a |
| Forward PE | 4.90 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $0.492 |
| Previous Close | $0.465 |
| Change ($) | 0.027 |
| Change (%) | 5.83% |
| Day's Open | 0.470 |
| Day's Range | 0.470 - 0.495 |
| Day's Volume | 2,701,891 |
| 52-Week Range | 0.330 - 1.450 |
Which penny stocks should you know about in 2021? Take a look at these 3 The post 3 Penny Stocks That Investors Need to Watch In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information |...
Reported Net Product Sales of $26.4 Million, Compared to Prior Year Pro-Forma Net Products Sales of $28.3 Million
Collaboration will Increase Access to CAMBIA and SPRIX through Cove's Innovative, and Continuous Online Physician Care Collaboration will Increase Access to CAMBIA and SPRIX through Cove's Innovative, a...
LAKE FOREST, Ill., April 22, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release first quarter 2021 financial results on Th...
It's never a dull day on the Reddit Penny Stocks subreddit and we're checking in to see what's being talked about the most today. The post 5 Reddit Penny Stocks Seeing the Most Chatter Thursday appeared...
Investors need to pay close attention to Assertio Holdings (ASRT) stock based on the movements in the options market lately.
Full Year Net Product Sales of $93.5 Million; Full Year Pro-Forma Revenue of $119.2 Million in Line with Guidance
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LAKE FOREST, Ill., March 01, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that Dan Peisert, President and Chief Executive Officer of Asse...
LAKE FOREST, Ill., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release fourth quarter and full year 2020 financial...
LAKE FOREST, Ill., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it closed its previously announced registered direct of com...
Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.
LAKE FOREST, Ill., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced it has entered into a securities purchase agreement with certain...
LAKE FOREST, Ill., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it closed its previously announced registered direct of com...
Assertio Holdings Inc (NASDAQ: ASRT) has entered into a securities purchase agreement with certain institutional investors to purchase 22.6 million common shares at $0.62 per share in a registered direc...
LAKE FOREST, Ill., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced it has entered into a securities purchase agreement with certain...
LAKE FOREST, Ill., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that its subsidiary Assertio Therapeutics, Inc. (“Assertio Thera...
Investors need to pay close attention to Assertio Holdings (ASRT) stock based on the movements in the options market lately.
Company Receives additional 180-day grace period, until June 28, 2021, to satisfy the $1.00 bid price requirement to maintain Nasdaq listing
LAKE FOREST, Ill., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, announced that President, chief exec...
Assertio Holdings, Inc. (ASRT) CEO Todd Smith on Q3 2020 Results - Earnings Call Transcript
Assertio (ASRT) delivered earnings and revenue surprises of 100.00% and 6.34%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LAKE FOREST, Ill., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, announced that the company will p...
Assertio Holdings, Inc. (ASRT) CEO Todd Smith on Q2 2020 Results - Earnings Call Transcript
Assertio (ASRT) delivered earnings and revenue surprises of -100.00% and -18.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Assertio Holdings (NASDAQ:ASRT) moved higher by 0.9% in pre-market trading after the company reported Q2 results.
Assertio Therapeutics (NASDAQ: ASRT) will be releasing its next round of earnings this Friday, August 07.
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LAKE FOREST, Ill., July 20, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today announced that its second quarter 2020 financ...
Assertio Therapeutics, Inc. (ASRT) CEO Arthur Higgins on Q1 2020 Results - Earnings Call Transcript
Assertio (ASRT) delivered earnings and revenue surprises of 225.00% and 85.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Assertio Therapeutics (NASDAQ:ASRT) rose 9% in pre-market trading after the company reported Q1 results.
-- Completed Strategic Asset Sales of NUCYNTA® Franchise and Gralise® Totaling $502.5 Million -- -- Repaid Senior Secured Debt in Full and Successfully Tendered for Convertible Debt --
Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
LAKE FOREST, Ill., April 08, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announced the completion and final results for its cash tender off...
Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1
LAKE FOREST, Ill., March 11, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announces that it has commenced cash tender offers (the “Offers”) ...
Assertio Therapeutics, Inc. (ASRT) CEO Arthur Higgins on Q4 2019 Results - Earnings Call Transcript
Assertio (ASRT) delivered earnings and revenue surprises of -200.00% and 17.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
During Q4 earnings call, Assertio (ASRT) is likely to provide an update on its recently implemented cost-saving initiatives and the sales performance of its marketed drugs.
Assertio Therapeutics: A Biotech Stock Trading Below Its Cash Balance
Also Announces its Senior Secured Debt Has Been Repaid in Full Also Announces its Senior Secured Debt Has Been Repaid in Full
Assertio (ASRT) closed at $1.35 in the latest trading session, marking a -0.74% move from the prior day.
Company Intends to Use Cash Proceeds to Retire its Outstanding Debt
Assertio (ASRT) closed the most recent trading day at $1.05, moving +0.48% from the previous trading session.
Assertio (ASRT) closed the most recent trading day at $1.11, moving -0.89% from the previous trading session.
Is (ASRT) Outperforming Other Medical Stocks This Year?
ASRT vs. PCRX: Which Stock Is the Better Value Option?
LAKE FOREST, Ill., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT), today announced the closing of its previously disclosed agreement (“Agree...
About ASRT
Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. The company's pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; moderate to severe ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of mi... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Nov 5, 1997 |
| Stock Exchange NASDAQ | Ticker Symbol ASRT |
Financial Performance
In 2020, ASRT's revenue was $106.28 million, a decrease of -53.69% compared to the previous year's $229.50 million. Losses were -$28.14 million, -87.04% less than in 2019.
Analyst Forecasts
According to 2 analysts, the average rating for ASRT stock is "Buy." The 12-month stock price forecast is 1.55, which is an increase of 214.85% from the latest price.